I think broker notes can be useful when they add another layer to an investment view.
They should not be followed blindly. Brokers can be wrong, forecasts can change, and target prices can move quickly. But when a broker's thesis lines up with my own view, I think it is worth paying attention.
Morgans currently has buy recommendations on the three ASX 200 shares in this article. I also rate all three as buys.
Image source: Getty Images
Xero Ltd (ASX: XRO)
The first ASX 200 share is Xero.
The small business accounting software company recently reported a better-than-expected FY26 result, and Morgans believes the FY27 outlook commentary was also ahead of expectations.
What I like about Xero is that it is no longer just an accounting software business in the narrow sense. It has the chance to become a more complete financial operating system for small businesses.
That could include accounting, payroll, invoicing, payments, tax, reporting, cash flow tools, and eventually more artificial intelligence (AI)-driven support.
Morgans noted that investors appeared cautious about the risk and reward from AI disruption. I can understand that. AI could change the way small businesses interact with software over time.
But I see AI as more of an opportunity than a simple threat for Xero. If management can use it to make the platform more valuable, save customers time, and unlock new monetisation options, I think the long-term runway remains attractive.
Morgans has retained its buy recommendation and $111 target price on the stock.
Breville Group Ltd (ASX: BRG)
Breville is another ASX 200 share I like.
This is a premium appliance business with a strong position in coffee machines, kitchen products, and other higher-quality household appliances.
What makes Breville interesting to me is the way it has built a global brand around better design, performance, and the at-home coffee routine. It is not just selling appliances. It is selling products that can become part of a daily habit.
Morgans is also positive on the stock. The broker pointed to encouraging updates from relevant offshore peers, including businesses with premium appliance exposure, innovation-led product development, coffee exposure, and geographic expansion.
That is a useful read-through for Breville because it suggests premium appliance demand has not disappeared, even with a challenging consumer backdrop.
I still think investors need to be realistic. Breville can be affected by consumer confidence, currency movements, tariffs, and competition.
But I like the company's brand, product pipeline, and international growth opportunity. In my view, it remains one of the better consumer growth shares on the ASX.
CSL Ltd (ASX: CSL)
The third ASX 200 share is CSL.
This has been a painful stock for many investors. The healthcare giant has faced downgrades, weaker confidence, and concerns around its plasma business.
Morgans recently reduced its forecasts and target price following CSL's downgrade of guidance. The broker pointed to issues including China albumin price pressure, US immunoglobulin channel inventory normalisation, paused Iran sales, and weaker sales in some areas.
However, the important point is that Morgans still has a buy recommendation, with a target price of $147.59.
I agree with the broader thinking. CSL's issues look serious, but I do not think they prove the business is structurally broken.
The company still has global leadership positions, large end markets, and exposure to healthcare demand that should continue to grow over time. Recovery may take years, and investors should not expect the old CSL story to simply reappear overnight.
But the valuation now looks much more interesting. If management can improve execution and rebuild confidence, I think patient investors could be rewarded.
Foolish takeaway
I like all three of these ASX 200 shares, but for different reasons.
What stands out is not simply that Morgans has buy ratings on them. It is that each stock has a credible path to being worth more over time, despite some clear risks.
Xero has a larger software opportunity ahead, Breville has a premium global brand, and CSL has recovery potential from a much lower level of confidence. For investors willing to be patient, I think all three are worth considering today.
